Funder: National Institutes of Health (NIH)

Due Dates: June 16, 2022 | October 16, 2022 | February 16, 2023 | June 16, 2023 | October 16, 2023 | February 16, 2024 | June 16, 2024 | October 16, 2024 | February 16, 2025

Funding Amounts: Up to $275,000 total direct costs over 2 years, with no more than $200,000 in any single year.

Summary: Supports early-stage exploratory research using bacteria, archaebacteria, bacteriophages, or non-oncolytic viruses and their products to study microbe-tumor-immune interactions and develop microbial-based cancer imaging, therapy, or diagnostics.

Key Information: Clinical trials are not allowed; foreign institutions and components are eligible; applications must address both microbial and tumor aspects; reissued as PAR-25-108 with expiration November 8, 2024.